NGM Biopharmaceuticals is Drug Discovery in United States that focus on NGM Biopharmaceuticals Inc business. Founded in 2008. They cover business area such as NGM Biopharmaceuticals Inc, novel therapeutic, scientific understanding, key biological pathway, cardio-metabolic, liver, oncologic and ophthalmic disease, aldafermin, nash, diabete, oncology, AMD, metabolic disease.
2008
( 16 years old in 2024 )
NGM Biopharmaceuticals Inc
-
333 Oyster Point Boulevard
South San Francisco, CA 94080
United States
Private
NGM Biopharmaceuticals Incnovel therapeuticscientific understandingkey biological pathwaycardio-metabolic, liver, oncologic and ophthalmic diseasealdaferminnashdiabeteoncologyAMDmetabolic disease
* We use standard office opening hours in near NGM Biopharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
NGM Biopharmaceuticals is Drug Discovery business from United States that founded in 2008 (16 years old in 2024), NGM Biopharmaceuticals business is focusing on NGM Biopharmaceuticals Inc.
NGM Biopharmaceuticals headquarter office and corporate office address is located in 333 Oyster Point Boulevard South San Francisco, CA 94080 United States.
NGM Biopharmaceuticals was founded in United States.
In 2024, NGM Biopharmaceuticals is currently focus on NGM Biopharmaceuticals Inc sector.
Above is snippet of Google Trends for "NGM Biopharmaceuticals Inc" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with NGM Biopharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
